Aspirin could help reduce COVID-19 mortality rate: claims study


Researchers at the George Washington University have established that a low dose of aspirin may help reduce the need for ICU admission, mechanical ventilation, and in-hospital mortality in patients suffering from the novel coronavirus.

Jonathan Chow, Managing Director, Assistant Professor of Anesthesiology and Critical Care medication, and the director of critical care anesthesiology fellowship at the George Washington of Medicine and Health Sciences, was reportedly quoted stating that after learning about the connection between blood clots and coronavirus, the team understood that aspirin which is used to prevent heart attack and stroke could prove to be vital for coronavirus- affected patients.

Chow added that the research team at GW University later found a strong association between low-dose aspirin and a considerable reduction in COVID-19 led deaths. Moreover, the low-cost and easy accessibility of aspirin will largely help in reducing the risk from some of the most lethal effects of the coronavirus.

It is worth noting that, more than 400 patients who were admitted in hospitals around the U.S. including those at the George Washington Hospital, Wake Forest Baptist Medical Center, the University of Maryland Medical Center, and the Northeast Georgia Health System between March 2020 to July 2020 were included in the study.

Seemingly, post adjusting for comorbidities and demographics, the use of aspirin led to a 44% decrease in the risk of mechanical ventilation, a nearly 47% reduction in in-hospitality mortality, and a 43% fall in ICU admissions. However, there was no change in overt thrombosis or major bleeding between the non-aspirin and aspirin users. 

Reportedly, the preliminary findings were initially published as a preprint during fall 2020. Since then, many other studies have approved the impact aspirin can have on preventing the infection as well as controlling the risk for severe coronavirus cases and death.

Source Credit: